PT  - JOURNAL ARTICLE
AU  - Andrew Atkeson
AU  - Michael Droste
AU  - Michael J. Mina
AU  - James H. Stock
TI  - Economic Benefits of COVID-19 Screening Tests
AID  - 10.1101/2020.10.22.20217984
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.22.20217984
4099  - http://medrxiv.org/content/early/2020/11/01/2020.10.22.20217984.short
4100  - http://medrxiv.org/content/early/2020/11/01/2020.10.22.20217984.full
AB  - We assess the economic value of screening testing programs as a policy response to the ongoing COVID-19 pandemic. We find that the fiscal, macroeconomic, and health benefits of rapid SARS-CoV-2 screening testing programs far exceed their costs, with the ratio of economic benefits to costs typically in the range of 2-15 (depending on program details), not counting the monetized value of lives saved. Unless the screening test is highly specific, however, the signal value of the screening test alone is low, leading to concerns about adherence. Confirmatory testing increases the net economic benefits of screening tests by reducing the number of healthy workers in quarantine and by increasing adherence to quarantine measures. The analysis is undertaken using a behavioral SIR model for the United States with 5 age groups, 66 economic sectors, screening and diagnostic testing, and partial adherence to instructions to quarantine or to isolate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported in part by NSF Rapid Grant 082359691.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:There are no human subjects in this project and no need for IRB approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used ihis paper is derived from publicly available sources and available from the authors upon request.